The above research results show that TPD52L2 is abnormally high expressed in ccRCC tissues and cells and is positively correlated with the malignant clinical characteristics of patients, which means that TPD52L2 is a potential carcinogen gene of ccRCC. This evidence concerns the gene TPD52L2 and nonpapillary renal cell carcinoma.